Liarozole

Liarozole
Names
Preferred IUPAC name
6-[(3-Chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-1,3-benzimidazole
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)
    Key: UGFHIPBXIWJXNA-UHFFFAOYSA-N
  • InChI=1/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)
    Key: UGFHIPBXIWJXNA-UHFFFAOYAV
  • C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4
Properties
C17H13ClN4
Molar mass 308.77 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Liarozole is a retinoic acid metabolism-blocking drug and aromatase inhibitor.[1] Liarozole is an isomer of alprazolam, but the two compounds are completely unrelated.

References

  1. ^ Vahlquist, A; Blockhuys, S; Steijlen, P; Van Rossem, K; Didona, B; Blanco, D; Traupe, H (2013). "Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: Results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial". The British Journal of Dermatology. 170 (1): 173–81. doi:10.1111/bjd.12626. PMC 4232915. PMID 24102348.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.